ClinicalTrials.gg
CompletedNCT02764762Updated Jul 14, 2023Results posted

Triple Combination Therapy in High Risk Crohn's Disease (CD)

A Phase 4 interventional study of Vedolizumab and Adalimumab in Crohn Disease, sponsored by Takeda. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
28th of 39
55 · median 101
Started
2017
with 4 others
Phase 4
14 of 39
3 open now
Registered
16th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 28th largest by enrollment, is one of 5 that started in 2017, is one of 14 in phase 4, and was the 16th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed CD stratified at higher risk for complications.

Read the detailed description

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have CD. This study will look at the endoscopic remission and mucosal healing of gastrointestinal tract of people who take vedolizumab as triple combination therapy with adalimumab and methotrexate.

The study will enroll approximately 60 participants. Participants will receive triple combination therapy which includes:

  • Vedolizumab 300 mg (intravenous)
  • Adalimumab 160/80/40 mg (subcutaneous)
  • Methotrexate 15 mg (oral)

All participants will receive vedolizumab intravenous infusion on Weeks 0, 2, 6, 14 and 22 along with adalimumab 160 mg, subcutaneous injection at Week 0, 80 mg at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with methotrexate tablets orally, once weekly from Weeks 0 up to Week 34. In monotherapy phase, all participants will receive vedolizumab intravenous infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.

This multi-center trial will be conducted in the United States and Canada. The overall time to participate in this study is 128 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a safety follow-up assessment. Participants will also participate in a long-term safety questionnaire, by phone, at 26 weeks (6 months) from the last dose of study drug.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has an initial diagnosis of CD established within 24 months prior to screening with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.
  2. Has moderate to severely active CD during Screening defined by a centrally assessed simple endoscopic score for Crohn disease (SES-CD) score >=7 (or >=4 if isolated ileal disease).

Exclusion criteria

Exclusion Criteria:

Gastrointestinal (GI) Exclusion Criteria

  1. Has a diagnosis of ulcerative colitis (UC) or indeterminate colitis.
  2. Has clinical evidence of a current abdominal abscess or a history of prior abdominal abscess.
  3. Has a known perianal fistula with abscess. (The participant may have a perianal fistula without abscess.)
  4. Has a known fistula (other than perianal fistula).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)

    In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.

    Drug: Vedolizumab · Drug: Adalimumab · Drug: Methotrexate

Interventions

  • Vedolizumab intravenous infusion.

    Also known as: Entyvio, MLN0002 IV

  • Adalimumab injection for subcutaneous use.

    Also known as: Humira

  • Methotrexate oral tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Endoscopic Remission at Week 26

    Endoscopic remission was defined as simple endoscopic score for Crohn's Disease (SES-CD) scale score from 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that was ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants Achieving Endoscopic Healing at Week 26

    Endoscopic healing was defined as SES-CD score ≤4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 26

  2. Percentage of Participants Achieving Endoscopic Response at Week 26

    Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 26

  3. Change From Baseline in SES-CD Score at Week 26

    The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Negative change indicates improvement.

    Time frame: Baseline and Week 26

  4. Percentage of Participants Achieving Deep Remission at Week 26

    Deep remission was defined as Crohn's disease activity index (CDAI) score \<150 and SES-CD score from 0-2. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 26

  5. Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26

    Clinical remission was defined as CDAI score \<150. Endoscopic response was defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI was scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 26

  6. Percentage of Participants Achieving Clinical Remission at Weeks 10 and 26

    Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 10 and 26

  7. Percentage of Participants Achieving Clinical Response at Weeks 10 and 26

    Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 10 and 26

  8. Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 10 and 26

    The change between the CRP levels were collected at Weeks 10 and 26 relative to Baseline. Negative change indicates improvement.

    Time frame: Baseline, Weeks 10 and 26

  9. Change From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 14, 26, 52, 78, and 102

    The change between the fecal calprotectin concentrations collected at Weeks 10, 14, 26, 52, 78, and 102 relative to Baseline were reported. Baseline is defined as the last observation prior to the first dose of the study drug.

    Time frame: Baseline, Weeks 10, 14, 26, 52, 78 and 102

  10. Percentage of Participants Achieving Clinical Remission and CRP <5 Milligram Per Liter (mg/L) at Weeks 26, 52, 78, and 102

    Clinical remission was defined as CDAI score \<150 and CRP level \<5 mg/L in participants with elevated CRP level at Baseline. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 26, 52, 78 and 102

  11. Percentage of Participants Using Oral Corticosteroids at Baseline Who Have Discontinued Corticosteroids and Are in Clinical Remission at Weeks 10, 26, and 102

    Percentage of participants using oral corticosteroids at Baseline who had discontinued corticosteroids and were in clinical remission at weeks 10, 26, and 102 were reported. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 10, 26 and 102

  12. Percentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102

    Clinical remission was defined as CDAI score \<150. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 52, 78 and 102

  13. Percentage of Participants Maintaining Clinical Response at Weeks 52, 78, and 102

    Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

    Time frame: Weeks 52, 78 and 102

  14. Percentage of Participants Maintaining Endoscopic Remission at Week 102

    Endoscopic remission was defined as SES-CD score 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicated more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 102

  15. Percentage of Participants Maintaining Deep Remission at Week 102

    Deep remission was defined as CDAI score \<150 and SES-CD score 0-2. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 102

  16. Percentage of Participants Maintaining Endoscopic Healing at Week 102

    Endoscopic healing was defined as SES-CD score \<=4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

    Time frame: Week 102

  17. Percentage of Participants Maintaining Endoscopic Response at Week 102

    Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 102

  18. Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102

    Clinical remission is defined as CDAI score \<150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to the nearest decimal value.

    Time frame: Week 102

  19. Percentage of Participants With First Exacerbation of CD

    First exacerbation of CD after 26 weeks was defined as either: 1) a CDAI increase of \>70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal OR 2) fecal calprotectin \>250 microgram per gram (mcg/g) alone. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 are seen with extremely severe disease. Percentages are rounded off to the nearest decimal value.

    Time frame: After 26 Weeks up to Week 120

07

Results

Posted Oct 21, 2021

Participant flow

Participants took part in the study at 23 investigative sites in Canada and United States from 18 April 2017 to 05 July 2022.

Participant flow — Overall Study
MilestoneVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Started55
Triple combination therapy55
Monotherapy45
Safety follow-up53
Completed16
Not completed39
Withdrew: Pretreatment event/adverse event9
Withdrew: Lost to follow-up4
Withdrew: Voluntary withdrawal8
Withdrew: Site termination1
Withdrew: Lack of efficacy16
Withdrew: Reason not specified1

Outcome measures

PrimaryPercentage of Participants Achieving Endoscopic Remission at Week 26

Endoscopic remission was defined as simple endoscopic score for Crohn's Disease (SES-CD) scale score from 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that was ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Remission at Week 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Percentage of Participants Achieving Endoscopic Remission at Week 2634.5 (21.1 to 48.0)
SecondaryPercentage of Participants Achieving Endoscopic Healing at Week 26

Endoscopic healing was defined as SES-CD score ≤4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Healing at Week 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Percentage of Participants Achieving Endoscopic Healing at Week 2643.6 (29.6 to 57.7)
SecondaryPercentage of Participants Achieving Endoscopic Response at Week 26

Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Response at Week 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Percentage of Participants Achieving Endoscopic Response at Week 2656.4 (42.3 to 70.4)
SecondaryChange From Baseline in SES-CD Score at Week 26

The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Negative change indicates improvement.

Time frame:
Baseline and Week 26
Reported as:
Mean · score on a scale
Change From Baseline in SES-CD Score at Week 26
score on a scaleVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Baseline12.6 ± 5.67
Change From Baseline at Week 26-8.9 ± 7.29
SecondaryPercentage of Participants Achieving Deep Remission at Week 26

Deep remission was defined as Crohn's disease activity index (CDAI) score \<150 and SES-CD score from 0-2. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Deep Remission at Week 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Percentage of Participants Achieving Deep Remission at Week 2621.8 (10.0 to 33.6)
SecondaryPercentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26

Clinical remission was defined as CDAI score \<150. Endoscopic response was defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI was scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 2638.2 (24.4 to 51.9)
SecondaryPercentage of Participants Achieving Clinical Remission at Weeks 10 and 26

Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 10 and 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Weeks 10 and 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Week 1060.0 (46.1 to 73.9)
Week 2654.5 (40.5 to 68.6)
SecondaryPercentage of Participants Achieving Clinical Response at Weeks 10 and 26

Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 10 and 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Weeks 10 and 26
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Week 1049.1 (35.0 to 63.2)
Week 2643.6 (29.6 to 57.7)
SecondaryChange From Baseline in C-reactive Protein (CRP) Levels at Weeks 10 and 26

The change between the CRP levels were collected at Weeks 10 and 26 relative to Baseline. Negative change indicates improvement.

Time frame:
Baseline, Weeks 10 and 26
Reported as:
Median · milligrams per liter (mg/L)
Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 10 and 26
milligrams per liter (mg/L)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)
Baseline7.60 (0.6 to 135.8)
Change From Baseline at Week 10-4.80 (-84.0 to 29.7)
Change From Baseline at Week 26-5.50 (-79.3 to 104.3)
SecondaryChange From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 14, 26, 52, 78, and 102

The change between the fecal calprotectin concentrations collected at Weeks 10, 14, 26, 52, 78, and 102 relative to Baseline were reported. Baseline is defined as the last observation prior to the first dose of the study drug.

Time frame:
Baseline, Weeks 10, 14, 26, 52, 78 and 102
Reported as:
Median · micrograms per gram
Change From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 14, 26, 52, 78, and 102
micrograms per gramVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)Vedolizumab 300 mg (IV)
Baseline1301.0 (23 to 17707)1210.0 (23 to 17707)
Change From Baseline at Week 10-864.0 (-16406 to 471)—
Change From Baseline at Week 14-556.0 (-14742 to 6892)—
Change From Baseline at Week 26-860.5 (-7911 to 440)—
Change From Baseline at Week 52—-350.0 (-7365 to 8021)
Change From Baseline at Week 78—-396.5 (-7844 to 9434)
Change From Baseline at Week 102—-452.0 (-8052 to 106)
SecondaryPercentage of Participants Achieving Clinical Remission and CRP <5 Milligram Per Liter (mg/L) at Weeks 26, 52, 78, and 102

Clinical remission was defined as CDAI score \<150 and CRP level \<5 mg/L in participants with elevated CRP level at Baseline. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 26, 52, 78 and 102
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission and CRP <5 Milligram Per Liter (mg/L) at Weeks 26, 52, 78, and 102
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)Vedolizumab 300 mg (IV)
Week 2651.3 (34.3 to 68.3)—
Week 52—44.1 (26.0 to 62.3)
Week 78—26.5 (10.2 to 42.8)
Week 102—20.6 (5.5 to 35.7)
SecondaryPercentage of Participants Using Oral Corticosteroids at Baseline Who Have Discontinued Corticosteroids and Are in Clinical Remission at Weeks 10, 26, and 102

Percentage of participants using oral corticosteroids at Baseline who had discontinued corticosteroids and were in clinical remission at weeks 10, 26, and 102 were reported. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 10, 26 and 102
Reported as:
Number · percentage of participants
Percentage of Participants Using Oral Corticosteroids at Baseline Who Have Discontinued Corticosteroids and Are in Clinical Remission at Weeks 10, 26, and 102
percentage of participantsVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)Vedolizumab 300 mg (IV)
Week 1050.0 (22.4 to 77.6)—
Week 2656.3 (28.8 to 83.7)—
Week 102—21.4 (0.0 to 46.5)
SecondaryPercentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102

Clinical remission was defined as CDAI score \<150. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 52, 78 and 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102
percentage of participantsVedolizumab 300 mg (IV)
Week 5250.0 (30.4 to 69.6)
Week 7833.3 (14.8 to 51.9)
Week 10220.0 (4.0 to 36.0)
SecondaryPercentage of Participants Maintaining Clinical Response at Weeks 52, 78, and 102

Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.

Time frame:
Weeks 52, 78 and 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Clinical Response at Weeks 52, 78, and 102
percentage of participantsVedolizumab 300 mg (IV)
Week 5266.7 (45.7 to 87.6)
Week 7845.8 (23.8 to 67.9)
Week 10229.2 (8.9 to 49.4)
SecondaryPercentage of Participants Maintaining Endoscopic Remission at Week 102

Endoscopic remission was defined as SES-CD score 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicated more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Endoscopic Remission at Week 102
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants Maintaining Endoscopic Remission at Week 10227.8 (4.3 to 51.2)
SecondaryPercentage of Participants Maintaining Deep Remission at Week 102

Deep remission was defined as CDAI score \<150 and SES-CD score 0-2. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Deep Remission at Week 102
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants Maintaining Deep Remission at Week 1028.3 (0.0 to 28.1)
SecondaryPercentage of Participants Maintaining Endoscopic Healing at Week 102

Endoscopic healing was defined as SES-CD score \<=4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.

Time frame:
Week 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Endoscopic Healing at Week 102
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants Maintaining Endoscopic Healing at Week 10234.8 (13.1 to 56.4)
SecondaryPercentage of Participants Maintaining Endoscopic Response at Week 102

Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Endoscopic Response at Week 102
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants Maintaining Endoscopic Response at Week 10250.0 (30.4 to 69.6)
SecondaryPercentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102

Clinical remission is defined as CDAI score \<150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to the nearest decimal value.

Time frame:
Week 102
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 10219.0 (0.0 to 38.2)
SecondaryPercentage of Participants With First Exacerbation of CD

First exacerbation of CD after 26 weeks was defined as either: 1) a CDAI increase of \>70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal OR 2) fecal calprotectin \>250 microgram per gram (mcg/g) alone. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 are seen with extremely severe disease. Percentages are rounded off to the nearest decimal value.

Time frame:
After 26 Weeks up to Week 120
Reported as:
Number · percentage of participants
Percentage of Participants With First Exacerbation of CD
percentage of participantsVedolizumab 300 mg (IV)
Percentage of Participants With First Exacerbation of CD62.2 (46.9 to 77.5)

Adverse events

Collected over From the first dose up to EOS (up to 120 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)0/55 (0%)6/55 (10.9%)36/55 (65.5%)
Vedolizumab 300 mg (IV)0/45 (0%)1/45 (2.2%)31/45 (68.9%)
Safety Follow-up0/53 (0%)2/53 (3.8%)4/53 (7.5%)
Most frequent serious events
Most frequent serious events
EventVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)Vedolizumab 300 mg (IV)Safety Follow-up
Small intestinal obstructionGastrointestinal disorders2/550/451/53
AppendicitisInfections and infestations0/551/450/53
Abdominal wall abscessInfections and infestations0/550/451/53
Colonic fistulaGastrointestinal disorders0/550/451/53
Crohn's diseaseGastrointestinal disorders1/550/450/53
GastroenteritisInfections and infestations1/550/450/53
LymphadenopathyBlood and lymphatic system disorders1/550/450/53
Perirectal abscessInfections and infestations1/550/450/53
PyrexiaGeneral disorders1/550/450/53
Most frequent other events
Showing 10 of 19
Most frequent other events
EventVedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)Vedolizumab 300 mg (IV)Safety Follow-up
Crohn's diseaseGastrointestinal disorders9/5520/454/53
ArthralgiaMusculoskeletal and connective tissue disorders10/553/450/53
RashSkin and subcutaneous tissue disorders3/555/450/53
NasopharyngitisInfections and infestations6/553/450/53
Abdominal painGastrointestinal disorders5/554/450/53
HeadacheNervous system disorders5/552/450/53
C-reactive protein increasedInvestigations1/554/450/53
CoughRespiratory, thoracic and mediastinal disorders2/554/450/53
Faecal calprotectin increasedInvestigations2/554/450/53
FatigueGeneral disorders4/551/450/53

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Mean32.4 ± 12.38
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Female24
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Hispanic or Latino1
Not Hispanic or Latino40
Unknown or Not Reported14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White49
More than one race1
Unknown or Not Reported0
Height
Height(cm)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Mean171.4 ± 9.55
Weight
Weight(kg)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Mean71.87 ± 18.373
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Mean24.26 ± 5.029
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral)
Canada14
United States41
08

Study locations

32 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Gastro Florida
    Clearwater, Florida 33761, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342-5000, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • Northshore University HealthSystem
    Evanston, Illinois 60201, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Cotton O'Neil Clinical Research
    Topeka, Kansas 66606, United States
  • Texas Digestive Disease Consultants Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Louisana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • Minnesota Gastroenterology, PA - Plymouth
    Plymouth, Minnesota 55446, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • Icahn School of Medicine at Mt. Sinai
    New York, New York 10029, United States
  • Digestive Health Partners, PS
    Asheville, North Carolina 28801, United States
  • Carolinas HealthCare System Digestive Health
    Charlotte, North Carolina 28204, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Options Health Research, LLC
    Tulsa, Oklahoma 74104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants Southlake
    Southlake, Texas 76092, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Texas Digestive Disease Consultants, Webster
    Webster, Texas 77598, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Digestive Health Specialists
    Tacoma, Washington 98405, United States
  • Covenant Health
    Edmonton, Alberta T6L 6K3, Canada
  • PerCuro Clinical Research Ltd
    Victoria, British Columbia V8V 3M9, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Toronto Digestive Disease Associates Inc
    Vaughan, Ontario L4L 4Y7, Canada
  • CIUSSS de I'Estrie-CHUS
    Sherbrooke, Quebec J1G 2E8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Sep 2020, 41 months.

Results were first posted in Oct 2021, 1 year after primary completion.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2016
First posted
May 6, 2016
StartActual
Apr 18, 2017
Primary completionActual
Sep 22, 2020
CompletionActual
Jul 5, 2022
Results first posted
Oct 21, 2021
Last update
Jul 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02764762
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 6, 2016
Start date
Apr 18, 2017
Primary completion
Sep 22, 2020
Completion
Jul 5, 2022
Results posted
Oct 21, 2021
Last update
Jul 14, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vedolizumab · Adalimumab · Methotrexate

Start the discussion